Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability
Authors:
- Min-Hee RyuMRMin-Hee Ryu
- Changhoon YooCYChanghoon Yoo
- Baek-Yeol RyooBRBaek-Yeol Ryoo
- Dae Ro ChoiDCDae Ro Choi
- Heung Moon ChangHCHeung Moon Chang
- Jae-Lyun LeeJLJae-Lyun Lee
- Mo Youl BeckMBMo Youl Beck
- Tae Won KimTKTae Won Kim
- Yoon-Koo KangYKYoon-Koo Kang
- 19 October 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 68 (2) , 285-291
Abstract
To evaluate the efficacy of nilotinib in patients with advanced gastrointestinal stromal tumors (GISTs) resistant or intolerant to both imatinib and sunitinib and to explore the potential relationship between nilotinib pharmacokinetics and clinical outcomes. We analyzed the efficacy, tolerability and pharmacokinetic parameters of nilotinib (400 mg twice daily) in 17 GIST patients with histories of prior gastrointestinal surgery. Median patient age was 59 years (range, 35-71 years), 14 of 17 patients (82.4%) were male, and mean body weight was 59.4 kg. Of the 17 patients, 2 (11.8%) had partial responses (PR), 10 (58.8%) had stable disease (SD), and 5 (29.4%) had progressive disease (PD), with a clinical benefit rate (CR + PR + SD) at 24 weeks of 47.0%. Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively. Most observed adverse events were mild (grade 1, 41.2%; grade 2, 52.9%), with no grade 3/4 events. Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L. The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014). Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks). Nilotinib was active and safe in patients with advanced GIST resistant to both imatinib and sunitinib. Major gastrectomy decreased the bioavailability of nilotinib and, in some patients, lowered its clinical activity.Keywords
This publication has 26 references indexed in Scilit:
- Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy ParticipantsThe Journal of Clinical Pharmacology, 2010
- A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal TumorsClinical Cancer Research, 2009
- Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal CancerDrug Safety, 2009
- Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometryJournal of Chromatography B, 2009
- Activity of Nilotinib (AMN-107) Alone in Advanced Gastrointestinal Stromal Tumors Progressing on Imatinib and SunitinibChemotherapy, 2009
- NilotinibClinical Cancer Research, 2008
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib MesylateJapanese Journal of Clinical Oncology, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002